SynAct Pharma AB
STO: SYNACT.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeppe Ovli Ovlesen
- Employees
- 6
- Headquarters
- Lund, Sweden
- IPO year
- 2016
- Market cap
- SEK 743.4M
- Website
- https://www.synactpharma.com
Loading SYNACT…
Loading profile data…Frequently asked questions about SYNACT
What does SynAct Pharma AB (SYNACT.ST) do?
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of i...
Where does SYNACT.ST trade?
SynAct Pharma AB (SYNACT.ST) trades on the Stockholm Stock Exchange.
What sector is SYNACT.ST in?
SynAct Pharma AB (SYNACT.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SynAct Pharma AB?
Jeppe Ovli Ovlesen is the chief executive officer of SynAct Pharma AB (SYNACT.ST).
Where is SynAct Pharma AB headquartered?
SynAct Pharma AB is headquartered in Sweden.
Does SYNACT.ST pay a dividend?
SynAct Pharma AB (SYNACT.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SYNACT.ST go public?
SynAct Pharma AB (SYNACT.ST) completed its initial public offering in 2016.